Narges Ansari 
1 
, Mansour Salesi 
2*  1
1 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan, Iran
        
	
        
        
Abstract
            Collapsing glomerulopathy is a rare but severe form of glomerular injury that can be accompanying  by SLE (systemic lupus erythematosus). The pathogenesis of collapsing glomerulopathy in lupus is not  well understood, and the treatment options are limited. The treatment of collapsing glomerulopathy  in lupus is challenging. Immunosuppressive therapy with corticosteroids and cytotoxic agents is the  mainstay of treatment. However, the response to therapy is often poor, and many patients progress to  end-stage renal disease despite treatment. The use of newer agents such as rituximab and belimumab  may offer additional options for the treatment of collapsing glomerulopathy in lupus. Further  studies are required to better detect the underlying mechanisms of collapsing glomerulopathy in  lupus and to develop more effective therapies for this condition.
        
        
 
        
	
            
            Implication for health policy/practice/research/medical education:  
  Collapsing glomerulopathy in lupus nephritis is associated with poor prognosis and rapid progression to end-stage renal disease.  
  Please cite this paper as: Ansari N, Salesi M. Lupus-associated collapsing glomerulopathy; a current data. J Nephropathol. 2024;13(4):e21528.  DOI: 10.34172/jnp.2024.21528.